Pgy 2 Program
Residency Program Director
-
Hallie Barr, PharmD, BCOP
- Pharmacy Manager, Investigational Drug Service
- Investigational Drugs and Research Residency Program Director
About the PGY2 Investigational Drugs and Research Residency Program
Residency Sites
The Ohio State University Wexner Medical Center (OSUWMC) is a 1,506 bed tertiary care medical center located in Columbus, Ohio. It is a multi-hospital delivery system recognized in 2018 as one of “America’s Best Hospitals” for excellence in ten specialties by US News and World Report based on quality, outcomes, and reputation. We are proud that we have one of the largest antimicrobial stewardship programs in the country and are focused on complete disease state management of patients with an emphasis on the use of rapid diagnostic testing.
Read MoreThe James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital will be the primary practice site for the Investigational Drugs and Research residency. The James is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer Institute, and is the third largest cancer center in the nation. Opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.
University Hospital (UH)
University Hospital (UH) will serve as an additional site serving patients and research in non-oncologic disease states. UH is our flagship hospital with over 900 beds and is a major referral center for patients throughout Ohio and the Midwest, and is one of the busiest kidney and pancreas transplant centers in the world. UH is also an international center for neuromodulation research and neurological care. In addition, UH is a level 1 trauma center in addition to being the American Burn Associated verified adult burn center for the region.
Key Rotations / Experiences
The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.
- Investigational Drug Service Core Experience
- Investigational Drug Service Leadership
- Clinical Trials Office (Oncology)
- Clinical Trials Management Office (Non-oncology)
- Office of Responsible Research Practices/Institutional Review Board
- Informatics – James Beacon Research Team
- Direct patient care:
- Phase 1 Clinical Treatment Unit
- Inpatient oncology
- Outpatient oncology
- Ambulatory infusion
- Drug Development Institute
- Teaching
- Longitudinal research/quality project
Key Preceptors
Hallie Barr, PharmD, BCOP
Pharmacy Manager, Investigational Drug Service
Kelley Barley, PharmD
Research Pharmacist
Jaimee Bible, PharmD
Research Pharmacist
Sebastian Biglione, BS, MLA, PharmD, PhD
Research Pharmacist
Paulo Andre Fernandes, PharmD, MS, BCPS
Research Pharmacist
Emily Harmon, PharmD
Research Pharmacist
Daniel Haas, MS, RPh
Research Pharmacist
Amanda Sabol, PharmD, BCPS
Research Pharmacist
Jennifer Severing, PharmD, BCPS
Research Pharmacist
Naomi Digiantonio, PharmD, BCPS
Generalist Pharmacist, Clinical Treatment Unit
Janinah Barreto, PharmD, MS, CPHIMS
Assistant Director, Pharmacy Informatics Clinical Apps
Jeffrey Patrick, PharmD
Director, Drug Development Institute
Sandra Meadows, MPH, CIP
Program Manager, Educational Programming and Regulatory Support
Office of Responsible Research Practices
Benefits and Additional Requirements
Application Deadline: January 10, 2022
Start Date: July 1, 2022
Annual Salary- $48,500
Vacation Days- 10 days
Staffing Requirement- 20 weekends per year
Completion of a Major Research Project

You must be logged in to post a comment.